mRNA 백신 및 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The mRNA Vaccine And Therapeutics Market size is expected to reach USD 114.50 Billion in 2034 from USD 31.74 Billion (2025) growing at a CAGR of 15.32% during 2026-2034.

The Global mRNA Vaccine and Therapeutics Market witnessed exponential growth following the successful deployment of mRNA-based COVID-19 vaccines. The technology demonstrated rapid development capabilities, high efficacy, and scalability, transforming vaccine research and production. Beyond infectious diseases, mRNA platforms are being explored for cancer immunotherapy, rare genetic disorders, and personalized medicine applications.

Key growth drivers include substantial government funding, ongoing R&D investments, and expanding biotech partnerships. Advances in lipid nanoparticle delivery systems and improved mRNA stability have strengthened clinical outcomes. The platform's adaptability allows quick modification to target emerging pathogens, making it highly valuable in global public health preparedness strategies.

Future prospects are exceptionally strong as pharmaceutical companies expand pipelines for oncology, autoimmune, and metabolic diseases. Continuous improvements in storage, distribution, and manufacturing processes will enhance commercial viability. As research broadens therapeutic indications, mRNA technology is expected to revolutionize modern medicine, ensuring sustained long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By mRNA Type

Nucleoside-modified mRNA

Unmodified mRNA

Self-amplifying mRNA

By Type

• Prophylactic
• Therapeutic

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Others (Respiratory Diseases, etc)

By End-user

• Hospitals & Clinics
• Biopharmaceutical Companies
• Others

COMPANIES PROFILED

• Moderna, Inc, BioNTech SE, CureVac SE, Arcturus Therapeutics, Inc, Sanofi, GSK plc, Argos Therapeutics Inc, Ethris, Pfizer Inc, AstraZeneca

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY MRNA TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Mrna Type
• 4.2. Nucleoside-modified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Unmodified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Self-amplifying mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Others Respiratory Diseases, etc Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Mrna Type
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Mrna Type
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Mrna Type
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Mrna Type
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Mrna Type
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MRNA VACCINE AND THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 ModernaInc
  • 10.2.2 BioNTech SE
  • 10.2.3 CureVac SE
  • 10.2.4 Arcturus TherapeuticsInc
  • 10.2.5 Sanofi
  • 10.2.6 GSK Plc
  • 10.2.7 Argos Therapeutics Inc
  • 10.2.8 Ethris
  • 10.2.9 Pfizer Inc
  • 10.2.10 AstraZeneca